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When the first titanium complex with anticancer activity was identified in the 1970s, it was attractive, 
based on the presence of the dichloride unit in TiCl2Cp2 (Cp = η-C5H5)2, to assume its mode of biological 
action was closely aligned with cisplatin [cis-PtCl2(NH3)2]. Over the intervening 40 years however a far 
more complicated picture has arisen indicating multiple cellular mechanisms of cellular action can be 
triggered by titanium anti-cancer agents. This tutorial review aims to unpick the historical data and 
provide new researchers, without an explicit cancer biology background, a contemporary interpretation of 
both older and newer literature and to review the best techniques for attaining the identities of the 
biologically active titanium species and how these interact with the cancer cellular machinery. 
 
Key learning points 
 
(1) Understanding the problems in defining ‘modes of action’ in order to effectively design small 
molecular titanium-based therapeutic, agents when moving beyond simple ‘structure vs. activity’ 
correlations. 
(2) The dangers of over generalisation in historical ‘mode of action’ proposals in the absence of rigorous 
control experiments leading to proposals not fully in line with all (especially later) observations.  
(3) Titanium induced cellular morphology changes and contemporary thoughts on mode(s) of action – 
presented in a way chemical scientists can ‘get to grips with them’ – understanding the hall marks of 
cellular death modes induced by titanium anti-cancer agents. 
(4) Modern tools for probing Ti-drug mechanisms of action, including: chiral probe complexes, added 
external proteins (transferrin, serum albumin); titanium solution speciation, and an overview of 
contemporary chemical-biology techniques of relevance to discovery of ‘modes/mechanisms of 
action’. 
 
1. Introduction 
 
Anti-cancer TiIVLn complexes are a current ‘hot’ area in bioinorganic chemistry.
1,2 They are attractive due 
to potential lower toxicity towards normal tissues (than traditional anti-cancer agents), and also due to 
an ability to tune cellular action through appropriate ligand choice. The high activities and multiple 
mechanisms of action shown by ‘new generation’ titanium-based species offer exciting potential for future 
clinical trial candidates; both in their own right and in combination with other therapeutic agents. This 
tutorial review is a ‘primer’ aimed at newcomers from the chemical sciences to this area who do not 
necessarily have any cancer biology background. A key requirement for any new drug to reach the clinic 
is that an active agents’ precise molecular and biological target(s) must first be well defined (the so 
called ‘mechanism of action’). Attaining this position for titanium-based pro-drugs is at the core of the 
discussion herein as it is the current bottleneck in developing ‘in clinic’ Ti-based therapies. The key issues 
are: (i) titanium anti-cancer agents can present opaque or conflicting biological data regarding their 
mechanisms of action and (ii) the precise structures of the active aqueous titanium species involved (and 
interaction with their exact biological targets) are still poorly defined, even though recent findings include 
many active compounds stable in water. Titanium(IV) species are potent Lewis acids which can interfere 
with a wide range of biological (Lewis basic) functions in any of the ~200 (cancer) cell types in the 
human body. Thus, perversely to the uninitiated, a single cytotoxic (cell ‘killing’) titanium complex can 
engender very different growth behaviour profiles against a range of cancer cell lines (Figure 1). The 
time-consuming nature of biological studies frequently limits the number of cell lines studied in an 
individual paper to a handful (at best). This can all too easily lead to over interpretation, and most 
particularly overgeneralisation of results (to other cell lines), posing risks for both the review writer (and 
new researchers) seeking to make general recommendations for improved titanium therapeutics. Modern 
cell line databases such as the NCI-60 (see also later†) can help in overcoming such issues, but 
historically this has been a significant problem.  
 
 
 
Figure 1. Titanocene dichloride (1) can engender cell line dependent inhibitory and proliferative effects. 
The concentration inducing a 50% reduction in cell population at a selected time, IC50 (sometimes related 
GI50 is used‡) is typically measured by cell staining, e.g. with the tetrazolium reagent MTT after exposure 
to 1 for a pre-selected time.  
 
For this reason we start this tutorial with an overview of ‘mode of action’ data attained for titanocene 
dichloride, TiCl2Cp2 (Cp; = η-C5H5)2 (1) during the early ‘discovery’ period 1979-2005, together with a 
summary of critical chemical biology of relevance to mode of action discovery. This is followed by an 
outline of more recent experiments (ca. 2005 onwards) indicating that alternative molecular targets 
might be perturbed, at least by complexes distinct from Cp2TiCl2, and that additional biological modes of 
action conclusions can be drawn (Section 3). After a discussion of contemporary mechanistic tools 
available for the identification of the active titanium therapeutic species and validation of biological 
modes of action (Section 4) we suggest some potential future paths and strategies for putative 
therapeutics (Section 5). 
 
2. Early titanium anti-cancer ‘mode(s) of action’ suggestions 
 
In the wake of Rosenburg’s seminal discovery (1965-69) of cancer inhibition by cis-PtCl2(NH3)2 (cisplatin) 
Köpf and Köpf-Maier reported the intuition-driven discovery of apparently related cytostatic (inhibition of cell 
growth) activity for the metallocene titanocene dichloride (1) in 1979.
3
 Finally, 1 reached Phase II clinical 
trial in the 1990s but did not progress due to lack of in patient efficacy. Initial mode of action studies on 1 
focused extensively on Ehrlich ascites tumours in mouse models (which presented highly encouraging ‘cure’ 
outcomes). DNA-binding, akin to cisplatin, was initially suggested by Köpf-Maier on the basis of: (i) 
suppression of synthesised DNA/RNA in tritium-labelled thymidine/uridine take up studies over 48 h, and (ii) 
the observation of apparent ‘high levels’ of titanium (in nucleic acid rich regions of cells exposed to 1) by X-
ray energy loss spectroscopy (EELS). Unfortunately, the low intensity of the EELS signals observed forced 
Köpf-Maier to use very high (up to 10 mM) concentrations of 1 (20-25 × the IC50 in this cell line) to detect 
any signal at all.  Subsequent fluorescence studies of V79 hamster lung cells treated with Cp2TiCl2 (100 μM) 
showed no significant difference in Ti-uptake compared to those not exposed (or indeed to those treated with 
other non-Ti metallocenes).
4 However, on the basis of the above experiments Ti uptake and intracellular 
delivery to a DNA target was typically assumed and proved a popular target for subsequent investigations 
and interpretations.  
 
Neutral 1 is very insoluble (< 5 μM) in water or cellular growth media and forms colloidal suspensions (even 
when genuine DMSO solutions of 1 are then subjected to subsequent aqueous dilution). By conductivity, 
after a 50 min induction period associated with its dissolution, Toney5 could estimate an effective net first 
order rate for cleavage of both chlorides in 1 of 0.84 h-1 (t½ ~50 min) to give [Cp2Ti(OH2)2]
2+ (3.5 mM in 
aqueous 0.32 M KNO3 at 37 
oC). By titration two pKa ionisation constants for the water ligands bound to 
Cp2Ti
2+ of 3.5 and 4.35 were attained. This means that at pH values ~3.5 the major species is 
[Cp2Ti(OH)(OH2)]
+ while [Cp2Ti(OH)2] should be present above pH 4.4 (blood serum pH is typically 7.3-
7.4). Although [Cp2Ti(OH)(OH2)]
+ has been potentially identified in the early stages of hydrolysis (δH Cp 
6.62, pHD 2.2 in D2O),
6 the dihydroxy complex has not: it readily loses water generating ‘Cp2Ti(O)’ 
species that are frequently insoluble and/or not easily charaterised by NMR. Ionisation of 1 and 
subsequent deprotonations of [Cp2Ti(OH2)2]
2+ are much faster (<15 min) in the presence of added bases. 
It has been suggested that [Cp2Ti(OH)(OH2)]
+ can act as an oestrogen mimic – the cause of the MCF-7 
proliferation seen in Figure 1.7 Free CpH is also detected upon aqueous dissolution of 1 but this Ti-Cp 
hydrolysis is actually rather slow (t½ ~102 h at 37 
oC in 0.32 M KNO3 at pH 7.5, based on appearance of 
CpH). Poorly characterised insoluble mixtures also result from these partial or complete Cp cleavages. 
What can be said is that the anti-cancer efficacy of the isolated polynuclear hydrolysis products 
[(Cp2TiCl)2(μ-O)] and [(CpTiCl(μ-O)]4 is less than that of 1 against Erhlich ascites (cure rates of 54 and 
38% in tumour-bearing mice vs. 100% for their equivalent treatment with 13). This might be taken to 
indicate that the causative anti-cancer agent contains only one titanium centre (but see also later in 
Section 3). Complexes containing substituted cyclopentandienes such as titanocene Y 3 (see Figure 5 for 
structure) hydrolyse much more slowly than 1 (ca. 72 h under ‘forcing’ model conditions: 60 oC, 10 mM 
in 1:1 D2O/DMSO) but no  intermediate was suggested.
8 
 
Based on the aqueous fragility of 1, Sadler suggested that the iron transport protein transferrin (Tf) might 
provide a ‘Trojan horse’ for the delivery of ‘labile’ Ti4+ species into ‘iron hungry’ cancer cells (Figure 2).9 He 
elegantly showed, that under physiological model conditions (100 mM NaCl, 25 mM hydrogencarbonate and 
4 mM phosphate, pH 7.4) that 1 is readily sequestered by apo (iron-free) transferrin as a Ti4+ species 
resulting from rapid (mins) loss of both chloride and cyclopentadienyl ligands from 1  – implicating 
biologically accelerated Cp-Ti hydrolysis (cf. Toney’s t½ ~102 h for Cp-Ti cleavage measured above). NMR 
studies of Tf metal-induced conformational change strongly support titanium binding to transferrin; Ti4+ from 
1 is first loaded to the C-lobe of transferrin followed by the N-lobe, resulting in a stable Ti2-Tf complex. It 
was proposed this Ti2-Tf complex is then intracellularly transported in membrane-bound compartments 
(endosomes) leading to release of Ti4+ ions on contact with cellular ATP and subsequent binding to DNA/RNA 
nucleic acid regions.10 While Sadler could show viable Ti2-Tf binding to Tf receptors on the surface of the cell 
(as Ti2-Tf blocked the uptake of radioactive 
59Fe-Tf into BeWo cells), mechanisms for the delivery of titanium 
(within the cell) to DNA remained more speculative. As an alternative to transferrin involvement for titanium 
delivery into cells the involvement of the ubiquitous blood protein serum albumin (SA) has been suggested 
as a delivery mechanism for titanocenes.7,8 Serum albumin receptors are overly represented on cancer cells 
and simple molecular modelling indicated a potential titanocene binding site (albeit with the chlorides not 
dissociated). 
 
 
 
Figure 2. Uptake of 1 by transferrin and the hypothesis that this provides a toxic intracellular Ti4+ species 
(of unknown structure) that interacts with DNA (and/or RNA).9 
 
Cisplatin (and its derivatives) are archetypal DNA interfering drugs, often used as reference compounds in 
anticancer research. The limitations of such platinum-based drugs include: efficacy against only a narrow 
range of tumours, acquired or intrinsic resistance, nephro- and gastrointestinal toxicity, nausea and bone 
marrow suppression. Alternatives are highly desired. There are clear indications that the mechanism of 
action of 1 is different from DNA coordinating cisplatin, as evidenced by differences in their nucleic acid 
metabolism and in the relative efficacy of 1 vs. cisplatin against the multiple different cell lines of the 
USA National Cancer Institute (NCI-60).† Additionally, 1 significantly overcomes acquired cisplatin 
resistance in some cell lines,11 e.g. 1 is still active in two human ovarian carcinoma cell lines (A2780CP 
and CH1-cisR) that are highly resistant to cisplatin. As cisplatin cytotoxicity is attained through DNA 
binding, cross-linking and ultimately strand breaks disrupting DNA replication and transcription, the 
resistance in the ovarian cell lines is directly related to an increased ability in the cancer cell to repair Pt-
induced DNA damage. As 1 is able to induce growth inhibitory activity in these same cell lines, the mode 
of action of 1 is less likely be related to formation of DNA adducts. Model Lewis acid/base metal-DNA 
solution binding experiments, using tritium (3H) labelled Cp ligands in 1 and isolated salmon testes DNA, 
allowed the average Ti-to-Cp ratio in the resultant DNA adducts to be determined. Reactions at pH 5.3 led to 
‘Cp2Ti’ binding, however, those at (more biologically relevant) pH 7 led to mostly to ‘CpTi’ adhesion and 
some (ca. 15%) non-Cp titanium species. The Ti uptake is rather slow (>2-6 h, pH 5-7 for 10 mM 1), as 
monitored by ICPMS, and no information is gained about potential site(s) of binding.12 Extraction of the DNA 
from human ovarian carcinoma cells (A2780), that had been treated with 1 (1 mM, 15 h), has also been 
carried out. It was found that it contained 15 μg Ti per gram of DNA isolated.11 Individual human cells 
contain about 7 picograms of DNA implying titanium burdens of only attomols (10-18) per cell – equivalent to 
the adhesion of only ca. 1 million molecules of 1 to a single cell. The titanium uptake in A2780 is also time-
dependant, cells treated for 2-6 h show DNA with little more than background levels of titanium. Fitting this 
picture, titration studies of 1 with DNA models (e.g. 5’-dGMP) at pH 7.0-7.4 indicate no binding, just 
independent hydrolysis of 1 in these freshly prepared samples (NMR data at 0-20 h).7  
The type of cell death induced by 1 or other titanium-anticancer agents can also be a hallmark of its 
mode of action, so these are now briefly overviewed (Figure 3). Depending on the external stimuli 
provided to the cell (by the anti-cancer, or indeed any other agent) three major forms of programmed 
cell death (PCD) can occur:  apoptosis (type 1), autophagy (type 2) or regulated necrosis (type 3). All 
three types can be characterised by cellular morphology changes and biochemical/biomolecular 
alterations (Figure 3).13 Apoptosis is the most common form of programmed cell death suggested for 1. 
Apoptotic cells undergo cell shrinkage, membrane blebbing (formation of cell membrane protrusions), 
DNA chromatin condensation, nuclear fragmentation and formation of apoptotic bodies.  
 
 
Figure 3. Types of programmed cell death induced by titanium-based agents. Paraptosis is distinct from, but 
related to necroptosis (type 3 PCD): cellular swelling is caused by extensive formation of intracellular 
(cytoplasmic empty) vacuoles, represented in part by  in the schematic. In more common necrosis only 
swelling of the cellular organelles is observed [based on ref. 13 and reproduced with permission].  
 
Autophagy (type 2 PCD) is a self-degradative process of programmed cell death. The initial step in 
autophagy is the formation of an isolation membrane, a small lipid bilayer membrane structure called a 
phagophore. The phagophore then expands in order to be loaded with intra-cellular cargo such as protein 
aggregates, organelles and ribosomes. This results in the formation of an autophagosome, a spherical 
double-membraned structure containing sequestered cargo. The loaded autophagosome then fuses with a 
spherical vesicle (lysosome) containing hydrolytic enzyme proteases, resulting in vesicle content 
degradation. Immunoblotting, immunoprecipitation and/or immunofluorescence analyses of key proteins 
that interact with the human autophagic machinery (most notably LC3, BECN1 and p62/SQSTM1) can 
allow detection of autophagy as a possible ‘mode of action’.14 It has been suggested to be involved for 
the fluoro analogue of 1 (Cp2TiF2)
15 and in agglomerated TiO2 nanoparticles (diameter ~1000 nm).
16 
 
Necroptosis (type 3 PCD). Necrosis is a form of cell death that is morphologically characterised by cellular 
swelling, rupture of the plasma membrane and loss of cytoplasmic contents. Inflammatory necrotic cell 
death is normally classified as a non-PCD. However, necrotic PCD is known and termed necroptosis to 
distinguish it. This PCD is controlled by specific signal pathways and metabolic breakdown of signal 
molecules. Cytotoxic agents have been reported to induce necroptosis when a cell cannot die via (type 1) 
apoptotic pathways. Among other related atypical cell death modes of relevance to titanium anti-cancer 
agents, paraptosis (which can be considered as a form of type 3 PCD), is of importance. It is both 
morphologically and biochemically distinct from apoptosis (no common morphological hallmarks) and is 
associated with extensive cytoplasmic vacuolisation and mitochondrial swelling resulting in cell rupture 
(Figure 3Ⱡ).17 Park reported vacuolisation, dilated ER and mitochondria in MH-S murine alveolar 
macrophages, by TiO2 nanosheets (ca. 400 × 400 × 2 nm) and concluded that induced paraptosis and 
late onset apoptosis were the mechanisms of action.18 
 
Even for the non-biologist, understanding the mechanistic links between PCD and cell division (the cell 
cycle) is of fundamental importance in developing effective routes to anti-cancer therapy. For example, 
cells respond to DNA damage by halting cell cycle progression. During such arrests, the cell ‘decides’ 
whether the DNA damage can be repaired. Multiple DNA repair mechanisms have evolved to ensure the 
integrity of genetic material (breakdown in DNA repair enzymes can predispose individuals to cancer). If 
DNA damage is extensive, the cells may trigger apoptosis. For example, the p53 gene is a tumour 
suppressor gene that is activated in response to diverse cellular stresses such as DNA damage, reduced 
oxygen levels and increased levels of tumour-gene expression. The p53 protein binds to DNA which in 
turn stimulates production of protein p21 that interacts with cell-division stimulating protein (cdk2). 
Complexation of p21 and cdk2 halts the cell from passing through the next stage of cell division. If 
inactivated through mutation p53 is unable to bind to DNA and as a consequence, the p21 protein is not 
activated and the cells continue to divide uncontrollably to form tumours.19 The cell actively halts 
progression through such cell cycle checkpoints as necessary. For the non-biologist, a simple reminder of 
the cell cycling process is given in Figure 4.  
 
 
Figure 4. Simplified cell cycling processes. After periods of growth and DNA replication called the 
interphase (G1+S+G2) nuclear division (mitosis) and cell division (cytokinesis) occurs. The interphase 
can be further subdivided into three sub-phases. In the G1 sub-phase, cell growth and synthesis of RNA 
and protein occurs. This is followed by S sub-phase where DNA synthesis takes place followed by G2, 
where cells continue to grow and produce new proteins required for cell division. 
 
The effects of anti-cancer titanium agents on the cell cycle can be interrogated by use of propidium iodide 
(PI) a DNA intercalating dye which fluoresces strongly when bound to DNA.  The DNA content of an 
individual cell is directly proportional to the fluorescence intensity of excited PI. A histogram of the DNA 
content of cells in a population can be used to ascertain what percentage of cells are in each phase of the 
cell cycle and how test compounds perturb this. Cells are permeabilised by fixation or through the use of 
a gentle detergent/hypotonic solution in order to allow the PI entry to the cell (to intercalate its DNA). 
The sub-G1 peak can be used as an indication of the proportion of the total cell population which possess 
hypoploid§ DNA content indicative of cells undergoing apoptosis. Ovarian A2780 tumour cells treated with 
1 (1 mM, 1.75 x IC50) showed S block (+30% at 15 h) and G2-M block (+23% at 24 h). However, at 
both earlier (6 h) and later (48 h) the cell cycle distributions are essentially identical to control cells, 
implying that the cell recovered to normal cycling after a short period after agent 1 exposure.11  
Interestingly, cell cycle studies at different intervals after agent 1 exposure (6, 12, 24 and 48 h) in both 
prostate cancer cell line PC3 and prostate normal epithelial cell line PwR-1E do not reveal any significant 
effect on the ratio of G1, S, or G2 phases of the closely related titanocenes X and Y (2-3, Figure 5) in 
A431 cells revealed anti-proliferative activity through cell cycle arrest, ultimately resulting in apoptosis. 
Titanocene X and Y caused G2/M block with a concomitant induction of apoptosis. In contrast, cisplatin 
treatment of the same cell line results in cell cycle arrest at S phase (inability to duplicate DNA due to 
cisplatin-DNA induced adducts), further suggesting that the apoptotic effects of 2-3 occurs via alternative 
mechanisms.20   
 
 
Figure 5. Structures of titanocene-X (2) and titanocene-Y (3). Complex 2 is isolated as a racemic mixture of 
the rac-diastereomer. 
 
Typically degradation of the cellular constituents initiated by PCD is achieved by a group of caspase 
enzymes (cysteine proteases) that break down the cellular proteins and peptides.҂ Caspases can be 
activated through two-distinct but convergent pathways, the intrinsic (mitochondria-mediated pathway) 
and the extrinsic (death receptor-mediated) pathway (Figure 6). Specific transmembrane tumour 
necrosis factor receptors (TNF) mediate the extrinsic apoptotic route. The binding of (protein) ligands 
with death receptors initiates the apoptosis cascade. For example, FasR, a death receptor involved in 
cellular proliferation, differentiation and apoptosis, binds to FasL, its (protein) ligand counterpart, 
resulting in clustering of the plasma membrane, initiating apoptosis. Caspase 8 can be activated via the 
Fas-associated death domain protein (FADD). This caspase cleaves the protein BID (a pro-apoptotic 
protein of the Bcl-2 family) resulting in crosstalk with the intrinsic mitochondrial pathway, thereby 
amplifying the apoptotic response. Activation of caspases-3, 6 and 7 results in cell death through 
proteolytic cleavage of diverse cellular targets.  
 
Apoptotic induction of A431 cells by titanocene Y (3) is dose- and time-dependent in caspase-3 and 7. 
However, no activation was detected for caspase-8. The use of the pan-caspase inhibitor Z-VAD-FMK, a 
cell-permanent molecule that irreversibly binds to the catalytic site of caspases, prevented apoptotic 
induction by titanocene Y (3) thus confirming that apoptosis is induced via a caspase-dependent pathway 
in this case.21 However, pre-incubation of PC-3 prostate cancer cells with Z-VAD-FMK failed to block 
apoptosis caused by 1 or titanocene Y (3) at 24 h.22 In order to assess whether titanocene Y 3 induced 
apoptosis by triggering the extrinsic (death receptor-mediated) pathway, the agent was tested against 
FasR death receptor deficient BJAB lymphoma cells. It was found these cells were more resistant to 
apoptotic induction by titanocene Y (3) and also showed a substantial increase (upregulation) of the Fas 
Ligand. This confirmed the role of FasR in the extrinsic cell death pathway. Similarly, MeIHO human 
melanoma cells (that overexpress a protein that inhibits apoptosis, anti-apoptotic Bcl-2) were also 
utilised to elucidate the role of the Bcl-2 protein in titanocene Y (3) apoptotic induction. However, it was 
found that apoptosis was triggered regardless of the expression of anti-apoptotic Bcl-2.23  
 
 
Figure 6. Activation of caspases (cysteine proteases) by the extrinsic and intrinsic apoptotic pathways. 
The circles () indicate activating proteins [based on ref. 13 and reproduced with permission]. 
 
In the early stages of apoptosis, plasma membrane cell surface changes result in the translocation of the 
phospholipid phosphatidylserine (PS) from the inner side to the outer layer of the plasma membrane 
(Figure 7). Thus, PS becomes exposed at the external surface of the cell. The Ca2+ dependent 
phospholipid binding protein Annexin V has a high affinity for PS, thus can be utilised as a sensitive probe 
for PS exposure at the external surface of the cell. During the initial stages of apoptosis, the cell 
membrane remains intact but later, the cell membrane loses its integrity and becomes ‘leaky’. Therefore, 
the stages of cell death can be determined by flow cytometry using Annexin V as a measurement of cell 
surface binding in conjunction with a dye exclusion test (e.g. fluorescent dyes such as propidium iodide, 
PI) that determines whether cell membrane integrity is lost. Thus, apoptotic (dying) or necrotic cell 
populations can be distinguished from healthy cells, which do not bind Annexin V and exclude PI.24  
 
Figure 7. Flow cytometry methods to distinguish between cells cycling normally and those entering 
apoptosis and dying by this route. 
 
3. Recent findings in titanium anti-cancer ‘mode(s) of action’ 
 
Hydrolysis of 1 and its simple derivatives to protein-bound ‘ligandless’ Ti-species seems to offer a straight 
forward process for the delivery of titanium into the cell (where its death is subsequently triggered). In 
an attempt to avoid the hydrolytic complexity of 1 Valentine25 and Tshuva2 introduced the use of multi-
dentate complexes of the type 4-5 (Figure 8). These species are rather more persistent in aqueous 
solution and their behaviour is not in accord with the involvement of the serum proteins Tf or SA as 
titanium transport vectors into the cell. 
 
Figure 8. Effects of the serum proteins transferrin (Tf) and serum albumin (SA) on complexes 1 and 3-
5. Studies were carried out at 37 oC with IC50 error bars of typically ±15-20% of the values reported 
above.1-2,7,25  
 
Unlike (1) and titanocene Y (3), complex 4 actually became less effective in the presence of physiological 
concentrations of Tf and SA [A549 cell line]. Similar, but less pronounced, behaviour was found for 3 
[HT-29 and OVCAR-1 cell lines] albeit at much lower apo-transferin concentrations. Although for 
metallocenes 1 and 3 anti-cancer activity is apparently increased by both Tf and SA – the concentrations 
used in the experiments of Figure 8 are well below physiological values. Complex 4 has been shown to be 
unstable with respect to metal exchange with iron(III) citrate at pH 7.4. Citrate serves as a significant 
non transferrin iron binder in human serum and is present at ~100 μM. This implies that 4 can act as an 
Fe(III) scavenger and this might adversely affect cancer cells disproportionately due to their greater 
metabolic iron requirement.26 In comparison to 4, compound 5 shows higher stability. 
 The fact that hydrolysis of 1, and related metallocenes, generate macroscopic insoluble Ti-based 
particulates (especially at longer time periods, ~days) can allow an alternative mechanism for titanium 
uptake/signalling via cellular particle envelopment (phagocytosis). Using model 20-30 nm TiO2 spheres 
Rashkow showed a Gaussian distribution of titanium burdens within SK-BR-3 breast cancer cells with an 
average of 26 picomol Ti/cell after exposure (range 0-1.7 nanomol/cell).27 Interestingly, none of the 
resulting intracellular TiO2 particulates (100-8000 nm in size) become associated with the nucleus but 
some are present in intracellular vacuoles. Studies of related ‘sheet-forms’ of TiO2 of dimensions 400 × 2 
nm also induced the formation of vacuoles and triggered both paraptosis and apoptosis in mouse-derived 
white blood lung cells (MH-S) when so treated (24 h, 10-20 μg ml-1, effective equivalent Ti concentration 
0.1-0.2 μM; but only 20% growth inhibition was attained).18 Interestingly, larger TiO2 spheres (~1000 nM 
diameter) do not induce paraptosis. 
 
One potential way to answer the question: “what causes the biological activity – true homogeneous 
titanium complexes or heterogeneous (and potentially ligandless) precipitates?” is through the use of 
chiral titanium complexes. Because of innate stereo-discrimination in biological receptors enantiomer 
dependent biological outcomes if triggered by truly homogeneous species, but not if hydrolysis and/or 
precipitation has taken place. In principle, the same approach is applicable to both titanocene dichloride 
complexes or heteroatom ligated Ti(IV) complexes as in the examples of Figure 9. Enantiopure titanocene 
dichlorides, that also demonstrate significant anti-cancer activity, are limited to (6) attained through 
asymmetric catalysis.28 The (S,S) enantiomer of 6 is significantly more cytostatic to MDA-MB-468 cells 
(GI50 11 μM, 24 h), than (R,R)-(6) which delivers weaker growth inhibition (GI50 23 μM) under the same 
conditions. This complex triggers cell death by paraptosis (see Section 2) in the same the same cell line 
and timeframe and its biological activity correlates strongly with the formation of spectroscopically 
characterised [CpR2Ti(OH)(OH2)]
+ cations CpR = C5H4CHEt(2-MeOC6H4). This species undergoes further 
hydrolysis to insoluble partially characterised [CpR2Ti=O]n species. The latter is also biologically active 
(GI50 5.5 μM against MDA-MB-468) but this is independent of the enantiomer of 6 used at 72 h 
exposure.28 One explanation is that the later activity is related to the ‘heterogeneous’ anti-cancer activity 
shown by sheet TiO2 (see above
18). The chiral ‘salan-based’ complexes of Tshuva and Manna show 
equally intriguing behaviour.29 The separate enantiomers of (7) show almost equipotency (IC50 ~5 μM, 72 
h) against HT-29 cells but a racemic (1:1) mixture of the same complexes is inactive against the same 
cell line. Complex (R,R)-8 (Y = Br) shows similar behaviour, but for closely related 7 (Y = H) the (S,S) 
enantiomer is significantly more active [IC50 39 μM vs. HT-29] than its (R,R) isomer [IC50 154 μM vs. HT-
29]. Diastereospecific formation of dimeric (as in Figure 7), or even trimeric species, that are the putative 
active anti-cancer agents have been suggested to account for the behaviour of (7-8). Fitting this picture 
those ‘salan-based’ complexes that are the most hydrolytically stable often exert the poorest biological 
performance. The inactivity of the isolated dimers (e.g. 9) was not at all consistent with such pictures. 
However, this appears to be an artefact caused by their poor aqueous solubility – when formulated as 
colloidal suspensions (average diameter 18 nm) activity against HT-29 was re-established [IC50 13 μM]. 
 
 
 
Figure 9. Representative enantiopure titanium complexes. 
 In 2009 Huhn reported that 10-11 were able to induce high cytotoxicity toward cervix tumour HeLa S3 
cells (Figure 10).30 Highly selective apoptotic (˃95%) induction was attained for 10, whereas necrosis 
accounted for ~50% cell death with 11. Salan-based-Ti
IV complexes of formula 12 were also reported to 
be highly active against various tumour cell lines but also against cisplatin-resistant human ovarian 
cancer cell lines (A2780CisR) and multi-drug resistant (ABCB1-expressing) mouse lymphoma cell lines 
HU-1 and HU-2. Such findings suggest that salan-based complexes are unaffected by cisplatin/multi-drug 
resistance mechanisms, and may provide further evidence against direct DNA coordination by such Ti(IV) 
complexes.  Analyses of the cell cycle distribution after LTi(OiPr)2 agent addition on T-25 lymphoma cells 
evidenced a greater percentage of treated cells accumulated at the G1 stage. This result was linked to 
upregulation of the tumour suppressor protein p53 (the growth regulator protein that protects against 
cellular damage, see Section 2). A significant increase of p53 levels in the T-25 cells was observed 
following incubation with LTi(OiPr)2. An apoptotic pathway was further supported via positive Annexin V 
early apoptotic binding.31 
 
 
Figure 10. Recent (2009-2016) highly active ‘salan-based’ titanium complexes. 
 
Cell cycle arrest at G1 was observed in both HT-29 and A2780 cell lines following LTi(OiPr)2 addition, 
suggesting an alternative mechanism of action compared to that of 1 (cell cycle mostly unaffected) and 
titanocene Y (3), which blocked cells at the G2/M phase.  Following incubation with LTi(OiPr)2, a 
significant increase in the p53 levels was observed in both cell lines whilst p21 was only detected in 
A2780 cells. Cleaved caspase 9 was also detected in both cell lines suggesting a caspase-dependent 
apoptotic pathway. Cellular accumulation of titanium in HT-29 and A2780 cells evidenced a gradual 
increase in accumulation in both cell lines as a function of agent incubation time. Comparison of the 
activity of 13 against the NCI-60 cell line panel reveals a unique profile suggesting that the mechanism 
of action of the titanium complex is distinct, and is not reflected in existing anti-cancer agents.32 Finally, 
direct comparison of titanium Y (3) and ‘salan-based’ complexes indicates that their mechanisms of 
action are different in MCF-7 and HT-29 cell lines.  For Ti-Salan-based species experiments revealed a 
slow but steady accumulation of titanium in the mitochondria after extended exposure (24 h). On the 
other hand, intracellular experiments following titanocene Y (3) exposure revealed only low levels 
thereby indicating that the bio-distribution of Ti in the cells is dependent on the Ti(IV) complex.33  Such 
studies indicate that bio-physical studies, while vital, can only provide a partial picture in such 
biochemically complex systems and that use of the full range of modern synthetic biology tools need to 
be deployed to provide comprehensive understanding. For this reasons both of these are overviewed in 
context next. 
 
4. Contemporary tools for determining titanium ‘mode(s) of action’ 
 
In biology, a mode of action describes a functional or anatomical change, at the cellular level, resulting 
from the exposure of cells or a living organism to a test agent or drug. In comparison, a mechanism of 
action describes perturbations at the molecular level. Initial light, bright field, fluorescence, microscopy, 
to determine morphological changes wrought by treatment of cells with test agents is a critical step and 
the first indication that agent under scrutiny is having an observable effect on cells. For example, the 
early observation of Köpf-Maier showing that Ehrlich ascites cells, following treatment with 1, underwent 
dramatic swelling although strongly indicative of necroptosis/paraptosis remained largely uncommented 
upon.3  Recent developments in instrumentation allow easier identification of cellular modes of activation.28 
Modern confocal and super-resolution microscopy34 can be utilised to probe mechanisms of action for 
example, individual γH2AX foci (visible sites of DNA damage) can be defined at areas of DNA double 
strand breaks but are not always informative, e.g. in Tinoco’s studies the morphology of A549 was 
unaffected by treatment with 4.25 Although higher resolution electron microscopy (scanning, 
transmission) is able to resolve cellular organelles in fine detail current associated EDAX detectors are not 
sensitive enough for titanium detections at the very low levels present in cells. Synchrotron-induced 
fluorescence offers better opportunities – but exact quantification is an issue. As seen in Section 2, 
through cells labelled with different fluorochromes flow cytometry (FC) offers the simplest way to attain 
multiparameter analysis of different cellular components or processes on a cell-by-cell basis. A number of 
analyses may be performed by flow cytometry including determination of cell cycle distribution, 
apoptosis, γH2AX quantification and reactive oxygen species generation in routine experiments easily 
carried out by chemical scientists.34-37 
 
When faced with a test agent whose activity has been validated, yet whose mechanism of action is 
unknown a number of interrogative techniques are available, some of which are briefly discussed here. 
Reacting to the explosion in kinase inhibitor research, high-throughput (HTP) kinase profiling has been 
developed by many organisations. The activity of hundreds of kinases can be compared in lysates of 
compound- and vehicle-treated cells. Alternatively, cell-free assays offer the opportunity to determine the 
effect of a given compound on activity of hundreds of kinases.  Screens utilise a number of techniques 
including radiometric and time-resolved fluorescence energy transfer (TR-FRET) analyses.38,39 The latter, 
a combination of time-resolved fluorometry (TRF) and Förster resonance energy transfer (FRET) offers a 
powerful tool for drug discovery researchers. To validate HTP assays, determination of phosphorylation 
should be conducted (e.g. Immunoblot profile kits or Western blot as outlined below). Custom screening 
options are available, in which kinases under investigation and compound concentrations can be selected 
by the researcher, allowing dose-response and IC50 profiles to be generated.  The ATP binding site is a 
common target for kinase inhibitors and thus ATP competition assays can be provided.  
 
Traditionally, proteomics (protein analysis) methodologies have relied upon separation of complex protein 
mixtures in samples by 2-dimensional gel electrophoresis: by isoectric point and molecular weight.40 
Patterns could be compared, and where changes were evident, protein identification involved isolation of 
protein spots, proteolysis, and mass analysis of each peptide prior to sequence database searched. 
Multidimensional Protein Identification Technology (MudPIT) eliminates the need for gel electrophoresis. 
Biochemical fractions/cell lysates containing many proteins are directly proteolysed and the enormous 
numbers of peptides generated are separated by 2-dimensional liquid chromatography. Tandem mass 
spectrometry (LC-MS/MS) is then employed to identify those proteins whose expression has been up- or 
down-regulated by the test agent.41 
 
Attaining the identity of the exact titanium entity responsible for a specific biological observation is a 
major challenge as hydrolysis of the precursor complexes typically occurs in the same time frame and 
distinguishing between soluble and insoluble species has been a recurrent problem in this area. Even in 
the case of species stable to ligand loss29 aggregation effects might occur and anti-cancer activity 
triggered by heterogeneous species is also known.18 Electrospray (ESI) analyses of the complex pro-drug 
dissolved in its cellular growth medium can provide a way to estimate the total Ti-species present as a 
function of time. If, in the same time frame, LCMS studies are also carried out disambiguation of solution 
vs insoluble species can be attained in favourable cases, as the latter are not eluted in the LCMS. For 6 
pairing such analyses confirmed formation of homogeneous [CpRTi(OH)(OH2)]
+ was commensurate with 
the onset of paraptosis.28 Disappearance of the latter led to the formation of insoluble precipitates, 
observed as protonated [CpR2TiO]2. Once identified this process could be kinetically modelled with high 
confidence, even though both the starting 6 and it eventual product are insoluble under aqueous 
conditions. Kinetic modelling of titanium speciation should be a powerful tool for identifying potential 
biologically active species – particularly if matched against the onset of biological outcomes. However, as 
the concentrations of the titanium species involved in real biological systems are low (μM) use of NMR 
has only recently become practical with the widespread availability of very high field (>600 MHz) 
instruments. 
 
A powerful tool which facilitates identification of protein targets of aqueous titanium species is offered by 
genome-wide short hairpin RNA (shRNA) library screens. Whole genome-, custom- and kinase-pooled 
lentiviral library screening is possible. In this technique, cells are transduced with human pooled shRNA 
library which may target >15000 human genes. Transduced cells are selected by survival in medium 
supplemented with antibiotic (e.g. 1 μg/mL puromycin; 4 days) before being treated with test agent (e.g. for 
72 h). Following isolation of genomic DNA, ShRNA sequences present in each sample are determined by next 
generation sequencing (NGS).42,43 Data are screened and analysed for parallel sequencing. A shRNA kinase 
pool has been developed which targets the human kinome and contains within the library ~745 genes 
commonly associated with development and disease, with an average of 12.6 shRNA clones per unique 
kinase gene. Enrichment, depletion and non-target controls are necessary to allow confidence in results. This 
method allows HTP screening of hundreds of genes (and kinases) to aid identification of genes essential for 
test agent activity/resistance.    
 
Upon identification of putative molecular targets and mechanisms of action, it is imperative to perform 
experiments to validate the findings. Quantitative polymerase chain reaction (qPCR) also known as real-time 
PCR, is a molecular biology technique to amplify and simultaneously quantify a specifically involved DNA 
sequences/genes.44 Thus, this technique can be used to validate a microarray experiment which indicated 
that treatment X resulted in up-regulation of gene γ expression.  Expression of gene(s) to be measured by 
qPCR require specific primers (short nucleic acid sequences typically 10 base pairs long) because the DNA 
polymerase enzymes that catalyse qPCR are only able to add nucleotides to existing DNA strands. The 
technique can generate thousands of copies of a single DNA sequence; expression data generated should 
always be normalised to a house-keeping gene (e.g. GAPDH). To determine whether up-regulation of gene Y 
translated to enhanced protein Y expression, or to validate proteomic techniques such as MudPIT, Western 
blot experiments may be performed. Proteins from whole cell lysates are separated by polyacrylamide gel 
electrophoresis (PAGE) and proteins electroblotted onto nitrocellulose or polyvinylidene difluoride (PVDF) 
membranes.45 Protein binding to membrane is a consequence of hydrophobic and charged interactions 
between membrane and protein. To pursue detection of a specific protein of interest, non-specific binding of 
antibodies to the membrane must first be blocked (typically using 5-10% dried milk in tris-buffered saline). 
Sequential incubation of membrane with primary antibody (1o Ab) raised artificially to recognise the protein 
of interest and 2o Ab (directed at the species-specific portion of the 1o Ab). The secondary antibody can be 
linked to a reporter enzyme such as horseradish peroxidase. A horseradish peroxidase-linked secondary is 
used to cleave a chemiluminescent agent, the reaction product produces luminescence in proportion to the 
amount of protein.  To validate results of a kinase profile array or to interrogate activation of a particular 
signal transduction cascade, 1o Abs recognising phosphorylated substrate can be used to measure protein 
phosphorylation. Levels of phosphorylated and total protein expression should be compared through use of 
2o Abs conjugated to enzymes for colourimetric or chemiluminescent detection. 
 
Finally, to validate the role of (a) protein(s) in the mechanism of action of, or mediation of resistance to test 
agents, gene transfection or knock-out (KO) techniques can be employed. Transfection is the non-viral 
deliberate introduction of genetic material [e.g. supercoiled plasmid DNA, small interfering RNA (siRNA)] 
protein or antibody into eukaryotic cells.46 Transfection of exogenous DNA into cells results in an isogenic cell 
line in which the protein of interest is expressed i.e. the only difference in the parent and its isogenic cell line 
partner is expression of gene under scrutiny. Conversely, transfection of siRNA into cells can lead to the 
knocking down of a gene of interest. The siRNAs used are 21–25 base pair double stranded RNA with 
dinucleotide 3' overhangs designed to be complementary to the mRNA of a target gene. One strand of the 
siRNA (the guide strand) complexes with a RNA-induced silencing complex (RISC).This complex then binds 
to complementary mRNA in the cell and cleaves it. This prevents translation of the target gene so the target 
protein is knocked down once the cell has turned over all previously synthesised protein. The knockdown 
achieved is transient, lasting typically between 3 and 7 days. To achieve stable knock-down, lentiviral short 
hairpin RNA constructs (sh RNA, introduced previously) may be transfected into cells. The isogenic cell lines 
generated, possessing either transfected protein or silenced gene, provide important tools in elucidation of 
molecular mechanisms of action and resistance. Subsequent analyses of cellular responses, following 
interrogation of isogenic cell lines with test agent allows determination of protein function.47 Gene targeting 
is a genetic technique that uses homologous recombination (HR) to permanently alter an endogenous gene. 
The targeting construct, containing (parts of) the gene to be modified, reporter gene and selectable marker, 
is generated in bacteria. This procedure may be used to delete a gene, add a gene, introduce genetic point 
mutations or splice variant genes. It enables creation of isogenic disease models facilitating development of 
personalised medicine particularly in the field of cancer.48 
 
The use of CRISPR Cas9-gRNA complex for genome editing was the American Association for the 
Advancement of Science's choice for breakthrough of the year in 2015.49 Clustered regularly interspaced 
short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base 
sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a 
bacteriophage virus or plasmid. The CRISPR/Cas system is a prokaryotic immune system that confers 
resistance to foreign genetic elements such as those present within plasmids and phages, and provides a 
form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognise and cut 
these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. Cas9 
was the first nuclease discovered, CRISPR/C2c2 from the bacterium Leptotrichia shahii is an RNA-guided 
CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or 
knock them down. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, 
the cell's genome can be excised at a desired location, allowing existing genes to be removed and/or new 
ones to be added.  CRISPR/Cas genome editing techniques have many potential applications, including 
validation of molecular mechanisms of action of drug candidates. 
 
The procedures outlined above are not exhaustive, but provide initial insight into experiments which may be 
undertaken, and sophisticated techniques which are available to enable elucidation of molecular mechanisms 
of action of experimental agents, drug candidates and clinical agents. Indeed, the complex genome-wide 
functional screens introduced, which warrant further reading to impart deeper understanding, have recently 
led to identification of genes and proteins affecting sensitivity to tamoxifen, a long-established anticancer 
drug.50 Genomic approaches maybe particularly profitable in the area of titanium-based anti-cancer agents 
as, to the best of our knowledge, there is not a reported incidence of cellular resistance developing in cell 
lines exposed to such agents, a clear distinction from Pt-based agents. 
 5. Conclusions: future paths and strategies for titanium therapeutics 
 
It can be concluded from this review that early ideas that titanium dichloride (1), and other related 
species, would function analogously to cisplatin were far from the ‘complete’ truth. To date about 10 
variously distinct mechanisms of action have been proposed for titanium-based therapeutics including: 
the triggering of apoptosis via DNA binding, inhibition of mitochondrial activity, induction of paraptosis 
(via kinase activation), the inactivation of topoisomerases and cell death by iron deprivation. It is also 
clear that heterogeneous particulates (nanoparticles), long assumed to be ‘unimportant’ decomposition 
products of the homogeneous titanium complexes provided to the cell actually can trigger a wide range of 
biological outcomes in their own right. Although the presence of such multiple biological activation modes 
makes understanding the exact behaviour of titanium-therapeutics challenging current chemical and bio-
chemical tools are now available making this a tractable proposition. In fact, opportunities to target 
multiple mechanisms of action are to be welcomed as they offer potential to tract heterogeneous disease 
by targeting multiple therapeutic pathways, thus improving clinical outcomes.  
 
Abbreviation list 
 
 
 
BECN1 An important 60 kDa signalling protein in autophagy and other PCD events. 
BID A 22 kDa signalling protein that stimulates release of cytochrome c from the 
mitochondria. 
Cdk2 Cyclin-dependent kinase 2, a ca. 33 kDa protein involved in cell cycle (G1) 
regulation. 
CRISPR Clustered regularly interspaced short palindromic repeats: DNA containing short 
repetitions of base sequences that, ultimately, the cell's genome can be cut at a 
desired location, allowing existing genes to be removed and/or new ones added. 
dGMP  Deoxyguanosine monophosphate, a derivative of the common nucleic acid 
guanosine triphosphate (GTP). 
FADD A 23 kDa adaptor (modifies signalling) protein involved in apoptotic triggering. 
FasL The transmembrane ligand protein that binds FasR activating it. 
FasR A cell surface bound protein which on ligand binding can trigger apoptosis. 
FC  Flow cytometry: Fluorescently labelled cells can be detected, counted and sorted by 
automated laser detection allowing rapid analyses of cell states and populations. 
LC3 Microtubule-associated protein light chain 3, a marker protein for autophagosomes. 
MTT The dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 
MudPIT Multidimensional Protein Identification Technology: a combined chromatography-MS 
technique for detecting proteins. 
p62/SQSTM1  A ubiquitin-binding protein mediating selective autophagy. 
PAGE  Polyacrylamide gel electrophoresis. 
PCD Programmed (as opposed to accidental) cell death. 
PDVF Polyvinylidene difluoride, [CH2CF2]n. 
PI The fluorescent DNA intercalator propidium iodide.  
PS Phosphatidylserine: a phospholipid and component of the cell membrane. 
qPCR  Quantified polymerase chain reaction. 
SA A non-specific 66 kDa binding protein for many (small molecule) biological signalling 
compounds 
ShRNA  Short hairpin RNA: used to silence target gene expression. 
siRNAs Small interfering RNA: used to induce short term silencing of protein coding genes. 
Tf The 79.6 kDa protein controlling biological iron concentration by Fe(III) binding. 
TNF Tumor necrosis factor: a group of cytokines (5–20 kDa signalling proteins) that can 
trigger apoptotic cell death. 
TR-FRET  Time-resolved fluorescence energy transfer: allowing the proximity of two 
appropriate fluorophores to be detected. 
Z-VAD-FMK  Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone – a global 
caspase inhibitor that irriversibly binds to the catalytic site. 
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Notes and references 
 
† The US National Cancer Institute (NCI) 60 drug screen compares the anti-cancer activity of a 
given compound against 60 carcinomer cell lines  from nine organ sites that acts as a ‘finger print’ of 
the agent’s mechanism of action (even if it is unknown).  
It is accessed via the web: https://dtp.cancer.gov/discovery_development/nci-60/ 
 
Over 140 titanium species had been screened by 2016 and their effect vs. the 60 separate cell lines. 
It provides clear evidence that titanium agents behave differently to the cisplatin family of drugs. 
For a recent application of such ‘COMPARE’ algorithm approaches, see ref. 32. 
 
‡ The difference between IC50 and GI50 is most easily seen by example. Consider a colony of 20 
tumour cells which untreated propagate to 100 cells (after time t, control). Against this control the 
concentration of agent that provides a population of 50 in the same time would be the IC50. As the 
total growth of the colony is (in this case) 100-20, the GI50 would be the concentration of agent 
resulting in 60 cells (80/2 + 20) here.  Such GI50 values are more useful for cytostatic (inhibiting) vs. 
cytotoxic (killing) agents. 
 
Ⱡ A short video clip of MDA-MB-468 (breast) cancer cells undergoing paraptosis is available as 
Electronic Supporting Information (ESI), see also reference 28. 
 
§ Having a chromosome number that is lower than the normal chromosome count for the species. 
 
҂ Although caspase independent apoptosis is also known, this is not discussed here as it has not 
(yet) been implicated in titanium-based anti-cancer agents to the best of our knowledge. 
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